

References

S-204

1. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Esophageal and esophagogastric junction cancers. Version 4.2021.
2. Mohan BP, Krishnamoorthi R, Ponnada S, Shakhatreh M, Jayaraj M, et al. Liquid nitrogen spray cryotherapy in treatment of Barretts esophagus, where do we stand? A systematic review and meta-analysis. *Dis Esophagus*. 2019;32(6).
3. Westerveld DR, Nguyen K, Banerjee D, et al. Safety and effectiveness of balloon cryoablation for treatment of Barrett's associated neoplasia: systematic review and meta-analysis. *Endosc Int Open*. 2020;8(02):E172-8.
4. Magee C, Lipman G, Alzoubaidi D, et al. Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia. *United European Gastroenterol J*. 2019;7(2):217-24.
5. Sharma P, Shaheen NJ, Katzka D, Bergman JJGHM. AGA clinical practice update on endoscopic treatment of barrett's esophagus with dysplasia and/or early cancer: Expert review. *Gastroenterology*. 2020;158(3):760-769.
6. Klair JS, Zafar Y, Nagra N, Murali AR, Jayaraj M, Singh D, et al. Outcomes of radiofrequency ablation versus endoscopic surveillance for barrett's esophagus with low-grade dysplasia: A systematic review and meta-analysis. *Dig Dis*. 2021;39(6):561-568.
7. Barret M, Pioche M, Terris B, Ponchon T, Cholet F, Zerbib F, et al. Endoscopic radiofrequency ablation or surveillance in patients with Barrett's oesophagus with confirmed low-grade dysplasia: A multicentre randomised trial. *Gut*. 2021;70(6):1014-1022.
8. Pouw RE, Klaver E, Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, et al. Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus: Long-term outcome of a randomized trial. *Gastrointest Endosc*. 2020;92(3):569-574.
9. Tariq R, Enslin S, Hayat M, Kaul V. Efficacy of cryotherapy as a primary endoscopic ablation modality for dysplastic barrett's esophagus and early esophageal neoplasia: A systematic review and meta-analysis. *Cancer Control*. 2020;27(1):1073274820976668.
10. Hamade N, Desai M, Thoguluva Chandrasekar V, Chalhoub J, Patel M, Duvvuri A, et al. Efficacy of cryotherapy as first line therapy in patients with Barrett's neoplasia: A systematic review and pooled analysis. *Dis Esophagus*. 2019;32(11):doz040.
11. Peng M, Guo X, Yi F, Shao X, Wang L, Wu Y, et al. Endoscopic treatment for gastric antral vascular ectasia. *Ther Adv Chronic Dis*. 2021;12:20406223211039696.
12. McCarty TR, Rustagi T. Comparative effectiveness and safety of radiofrequency ablation versus argon plasma coagulation for treatment of gastric antral vascular ectasia: A systematic review and meta-analysis. *J Clin Gastroenterol*. 2019;53(8):599-606.
13. Magee C, Graham D, Leonard C, McMaster J, Davies H, Skotchko M, Lovat L, et al. The costeffectiveness of radiofrequency ablation for treating patients with gastric antral vascular ectasia refractory to first line endoscopic therapy. *Curr Med Res Opin*. 2020;36(6):977-983.
14. Magee C, Lipman G, Alzoubaidi D, Everson M, Sweis R, Banks M, et al. Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia.

United European Gastroenterol J. 2019;7(2):217-224.

15. Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. *Am J Gastroenterol.* 2022; 117(4): 559-587.
16. Agarwal S, Alshelleh M, Scott J, et al. Comparative outcomes of radiofrequency ablation and cryoballoon ablation in dysplastic Barrett's esophagus: a propensity score-matched cohort study. *Gastrointest Endosc.* 2022; 95(3): 422-431.e2.
17. Fasullo M, Shah T, Patel M, et al. Outcomes of radiofrequency ablation compared to liquid nitrogen spray cryotherapy for the eradication of dysplasia in barrett's esophagus. *Dig Dis Sci.* Jun 2022; 67(6): 2320-2326.
18. Wang Y, Ma B, Yang S, et al. efficacy and safety of radiofrequency ablation vs. endoscopic surveillance for barrett's esophagus with low-grade dysplasia: Meta-analysis of randomized controlled trials. *Front Oncol.* 2022; 12: 801940.